Form 4/A for INMB Inmune Bio, Inc.

Accepted 2021-09-08 00:00:00 ET · period of report 2021-06-10 · accession 0001415889-21-004279 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
A	2021-09-08	2021-06-10	INMB	Xencor Inc	10%	J - Other	$17.14	+192.5K	1.78M	+12%	+$3.30M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-06-10	J	A	192,533	$17.14	1,777,533	D	—	—	(F2) On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock. (F1) On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.